EC-103

EC-103 is a preclinical-stage bispecific antibody being developed by ExoCan Healthcare Technologies for applications in immuno-oncology. As a bispecific agent, the molecule is designed to simultaneously engage two distinct antigens, a strategy typically employed to enhance immune cell recruitment to tumors or to achieve dual checkpoint inhibition. ExoCan, an India-based biotechnology firm, focuses on oncology therapeutics and exosome-based technologies; EC-103 represents their expansion into multi-specific biologics. While the specific molecular targets of EC-103 have not been publicly disclosed, the asset is positioned within the company's therapeutic pipeline to address unmet needs in cancer immunotherapy.